drugset / Trial / NCT03042325
Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of alogliptin tablets when given as monotherapy or add on therapy in participants who are on standard care for management of Type 2 Diabetes Mellitus (T2DM).
Timeline
- Start
- 2017-07-30
- Primary completion
- 2018-01-15
- Completion
- 2018-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alogliptin | Unknown | 6.25 mg | Oral |
| Subject | Alogliptin | Unknown | 12.5 mg | Oral |
| Subject | Alogliptin | Unknown | 25 mg | Oral |